Pathophysiology of Cardiorenal Syndrome and Use of Diuretics and Ultrafiltration as Volume Control

Area of Science:

• Cardiology
• Nephrology
• Cardiorenal Medicine

Background:

• Cardiorenal syndrome (CRS) involves heart and kidney dysfunction.
• Venous congestion is increasingly recognized as a key factor in CRS pathophysiology.
• Understanding this interaction is crucial for managing heart failure patients with renal impairment.

Purpose of the Study:

• To review the pathophysiology of venous congestion in heart failure-related renal impairment.
• To evaluate the role of diuretics and ultrafiltration in treating CRS.
• To discuss the need for precise volume assessment in CRS management.

Main Methods:

• Literature review focusing on venous congestion in CRS.
• Analysis of clinical studies on decongestive therapies (diuretics, ultrafiltration).
• Examination of evidence regarding the impact of these therapies on renal function and mortality.

Main Results:

• Decongestive therapy effectively reduces volume overload and improves symptoms in CRS.
• The impact of diuretics or ultrafiltration on improving kidney function or reducing mortality in CRS is uncertain.
• Accurate assessment of volume status is essential for effective decongestion.

Conclusions:

• Venous congestion is a critical element in cardiorenal syndrome.
• Current decongestive strategies offer symptomatic relief but lack definitive evidence for improving renal outcomes or survival.
• Objective measures of renal venous congestion may guide future therapeutic decisions in CRS.